Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Despite instructions of closure by federal authorities tomorrow, many compounded versions of weight-loss drugs are available ...

Antiobesity medications tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...